Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)

11 november 2026 uppdaterad av: Istituto Auxologico Italiano

Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study

The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).

Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).

Studietyp

Observationell

Inskrivning (Beräknad)

300

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

16 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Consecutive patients referred to the Syncope Unit for severe unexplained syncope

Beskrivning

Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.

Exclusion Criteria: Non-severe syncope Definitions.

  • Unexplained syncope is defined as unexplained etiology or unexplained

  • Severe syncope is defined by the presence of one or more among the following:

    1. Suspected life-threatening arrhythmias

    2. Substantial impact on patient's quality of life (QoL)

      • Frequent episodes
      • Restriction of educational or occupational activities (including, but not limited to, unemployment)
      • Restriction of social or daily-life activities, e.g. when syncope occurs while driving
    3. High risk of clinically significant outcomes

      • Syncope associated with major injuries/trauma, i.e. head injury or fractures
      • Unpredictable syncope, i.e. without prodrome or identifiable triggers
    4. Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure

    5. Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope

  • Non-severe syncope is defined by the presence of one or more among the following:

    1. Sporadic (isolated) episodes without major impact on patient's QoL
    2. Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Unexplained syncope

Syncope Unit

At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Tidsram: through study completion, an average of 1 year
through study completion, an average of 1 year

Sekundära resultatmått

Resultatmått
Tidsram
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Tidsram: through study completion, an average of 1 year
through study completion, an average of 1 year
Assessment of number and costs of resource utilization associated to the clinical practices
Tidsram: through study completion, an average of 1 year
through study completion, an average of 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

31 december 2026

Primärt slutförande (Beräknad)

31 december 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

5 september 2026

Först inskickad som uppfyllde QC-kriterierna

11 november 2026

Första postat (Faktisk)

17 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera